HC Wainwright Reaffirms Buy Rating for Femasys (NASDAQ:FEMY)

Femasys (NASDAQ:FEMY)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $12.00 price objective on the stock.

Separately, Chardan Capital decreased their target price on shares of Femasys from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th.

Femasys Stock Performance

NASDAQ FEMY opened at $1.03 on Tuesday. The company has a quick ratio of 5.93, a current ratio of 6.47 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $22.90 million, a P/E ratio of -1.27 and a beta of -2.83. Femasys has a 52-week low of $0.73 and a 52-week high of $2.40. The firm has a 50-day moving average price of $1.16 and a 200 day moving average price of $1.15.

Femasys (NASDAQ:FEMY) last issued its earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). Femasys had a negative return on equity of 120.13% and a negative net margin of 1,435.77%. The business had revenue of $0.55 million for the quarter, compared to analysts’ expectations of $0.40 million. Equities research analysts expect that Femasys will post -0.79 EPS for the current year.

Hedge Funds Weigh In On Femasys

An institutional investor recently raised its position in Femasys stock. CM Management LLC grew its position in Femasys Inc. (NASDAQ:FEMY) by 6.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 425,000 shares of the company’s stock after buying an additional 25,000 shares during the quarter. CM Management LLC owned 1.91% of Femasys worth $484,000 at the end of the most recent quarter. Institutional investors own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.